Lundgren Lundgren

Dr. Lundgren Lundgren


Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 August 2014 in Trials
Verified
Journal Article
Open access
PDF file
Roger Olofsson BaggeRoger Olofsson Bagge
Roger Olofsson Bagge
Lars NyLars Ny
Lars Ny
MEMalin Sternby Eilard
Malin Sternby Eilard
MRMagnus Rizell
Magnus Rizell
CCChristian Cahlin
Christian Cahlin
PLPer Lindnér
Per Lindnér
Uveal melanoma is the most common primary intraocular malignancy in adults. Despite successful control of the primary tumor, metastatic disease will ultimately develop in approximately 50% of patients, with the liver being the most common site for metastases. The median survival for patients with liver metastases is between 6 and 12 months, and no treatment has in randomized trials ever been shown to prolong survival. A previous phase II trial using isolated hepatic perfusion (IHP) has suggested a 14-month increase in overall survival compared with a historic control group consisting of the longest surviving patients in Sweden during the same time period (26 versus 12 months). This is the protocol for a multicenter phase III trial randomizing patients with isolated liver metastases of uveal melanoma to IHP or best alternative care (BAC). Inclusion criteria include liver metastases (verified by biopsy) and no evidence of extra-hepatic tumor manifestations by positron emission tomography–computed tomography (PET-CT). The primary endpoint is overall survival at 24 months, with secondary endpoints including response rate, progression-free survival, and quality of life. The planned sample size is 78 patients throughout five years. Patients with isolated liver metastases of uveal melanoma origin have a short expected survival and no standard treatment option exists. This is the first randomized clinical trial to evaluate IHP as a treatment option with overall survival being the primary endpoint. ClinicalTrials.gov registration number: NCT01785316 (registered 1 February 2013). EudraCT registration number: 2013-000564-29.

9 December 2019 in Cancers
Verified
Journal Article
Open access
PDF file
LNLazaro Hiram Betancourt Nunez
Lazaro Hiram Betancourt Nunez
ASA. Marcell Szasz
A. Marcell Szasz
Magdalena KurasMagdalena Kuras
Magdalena Kuras
JMJimmy Rodriguez Murillo
Jimmy Rodriguez Murillo
YSYutaka Sugihara
Yutaka Sugihara
György Marko-VargaGyörgy Marko-Varga
György Marko-Varga
In comparison to other human cancer types, malignant melanoma exhibits the greatest amount of heterogeneity. After DNA-based detection of the BRAF V600E mutation in melanoma patients, targeted inhibitor treatment is the current recommendation. This approach, however, does not take the abundance of the therapeutic target, i.e., the B-raf V600E protein, into consideration. As shown by immunohistochemistry, the protein expression profiles of metastatic melanomas clearly reveal the existence of inter- and intra-tumor variability. Nevertheless, the technique is only semi-quantitative. To quantitate the mutant protein there is a fundamental need for more precise techniques that are aimed at defining the currently non-existent link between the levels of the target protein and subsequent drug efficacy. Using cutting-edge mass spectrometry combined with DNA and mRNA sequencing, the mutated B-raf protein within metastatic tumors was quantitated for the first time. B-raf V600E protein analysis revealed a subjacent layer of heterogeneity for mutation-positive metastatic melanomas. These were characterized into two distinct groups with different tumor morphologies, protein profiles and patient clinical outcomes. This study provides evidence that a higher level of expression in the mutated protein is associated with a more aggressive tumor progression. Our study design, comprised of surgical isolation of tumors, histopathological characterization, tissue biobanking, and protein analysis, may enable the eventual delineation of patient responders/non-responders and subsequent therapy for malignant melanoma.

27 February 2013 in Clinical and Translational Medicine
Verified
Journal Article
Open access
PDF file
CWCharlotte Welinder
Charlotte Welinder
Göran JönssonGöran Jönsson
Göran Jönsson
CIChristian Ingvar
Christian Ingvar
LLLundgren Lundgren
Lundgren Lundgren
HOHåkan Olsson
Håkan Olsson
GMGyörgy Marko‐Varga
György Marko‐Varga
Background: The objectives and goals of the Southern Swedish Malignant Melanoma (SSMM)are to develop, build and utilize cutting edge biobanks and OMICS platformsto better understand disease pathology and drug mechanisms. The SSMMresearch team is a truly cross‐functional group with members from oncology, surgery, bioinformatics, proteomics, and genomics initiatives. Within theresearch team there are members who daily diagnose patients with suspectmelanomas, do follow‐ups on malignant melanoma patients and remove primaryor metastatic lesions by surgery. This inter‐disciplinary clinical patientcare ensures a competence build as well as a best practice procedure wherethe patient benefits.Methods: Clinical materials from patients before, during and after treatments withclinical end points are being collected. Tissue samples as well as bio‐fluidsamples such as blood fractions, plasma, serum and whole blood will bearchived in 384‐high density sample tube formats. Standardized approachesfor patient selections, patient sampling, sample‐processing and analysisplatforms with dedicated protein assays and genomics platforms that willhold value for the research community are used. The patient biobank archivesare fully automated with novel ultralow temperature biobank storage unitsand used as clinical resources.Results: An IT‐infrastructure using a laboratory information management system (LIMS)has been established, that is the key interface for the research teams inorder to share and explore data generated within the project. The cross‐sitedata repository in Lund forms the basis for sample processing, together withbiological samples in southern Sweden, including blood fractions and tumortissues. Clinical registries are associated with the biobank materials, including pathology reports on disease diagnosis on the malignant melanoma(MM) patients.Conclusions: We provide data on the developments of protein profiling and targeted proteinassays on isolated melanoma tumors, as well as reference blood standardsthat is used by the team members in the respective laboratories. These pilotdata show biobank access and feasibility of performing quantitativeproteomics in MM biobank repositories collected in southern Sweden. Thescientific outcomes further strengthen the build of healthcare benefit inthe complex challenges of malignant melanoma pathophysiology that isaddressed by the novel personalized medicines entering the market.

27 February 2025 in Cancers
Verified
Journal Article
Open access
PDF file
Magdalena KurasMagdalena Kuras
Magdalena Kuras
LNLazaro Hiram Betancourt Nunez
Lazaro Hiram Betancourt Nunez
RHRunyu Hong
Runyu Hong
LSLeticia Szadai
Leticia Szadai
JRJimmy Rodriguez
Jimmy Rodriguez
György Marko-VargaGyörgy Marko-Varga
György Marko-Varga
Background: Melanoma is a highly heterogeneous disease, and a deeper molecular classification is essential for improving patient stratification and treatment approaches. Here, we describe the histopathology-driven proteogenomic landscape of 142 treatment-naïve metastatic melanoma samples to uncover molecular subtypes and clinically relevant biomarkers. Methods: We performed an integrative proteogenomic analysis to identify proteomic subtypes, assess the impact of BRAF V600 mutations, and study the molecular profiles and cellular composition of the tumor microenvironment. Clinical and histopathological data were used to support findings related to tissue morphology, disease progression, and patient outcomes. Results: Our analysis revealed five distinct proteomic subtypes that integrate immune and stromal microenvironment components and correlate with clinical and histopathological parameters. We demonstrated that BRAF V600-mutated melanomas exhibit biological heterogeneity, where an oncogene-induced senescence-like phenotype is associated with improved survival. This led to a proposed mortality risk-based stratification that may contribute to more personalized treatment strategies. Furthermore, tumor microenvironment composition strongly correlated with disease progression and patient outcomes, highlighting a histopathological connective tissue-to-tumor ratio assessment as a potential decision-making tool. We identified a melanoma-associated SAAV signature linked to extracellular matrix remodeling and SAAV-derived neoantigens as potential targets for anti-tumor immune responses. Conclusions: This study provides a comprehensive stratification of metastatic melanoma, integrating proteogenomic insights with histopathological features. The findings may aid in the development of tailored diagnostic and therapeutic strategies, improving patient management and outcomes.

24 March 2020 in Cancers
Verified
Journal Article
Open access
PDF file
YKYonghyo Kim
Yonghyo Kim
Jeovanis Gil ValdesJeovanis Gil Valdes
Jeovanis Gil Valdes
IPIndira Pla
Indira Pla
ASAniel Sanchez
Aniel Sanchez
LNLazaro Hiram Betancourt Nunez
Lazaro Hiram Betancourt Nunez
György Marko-VargaGyörgy Marko-Varga
György Marko-Varga
Malignant melanoma is among the most aggressive skin cancers and it has among the highest metastatic potentials. Although surgery to remove the primary tumor is the gold standard treatment, once melanoma progresses and metastasizes to the lymph nodes and distal organs, i.e., metastatic melanoma (MM), the usual outcome is decreased survival. To improve survival rates and life span, advanced treatments have focused on the success of targeted therapies in the MAPK pathway that are based on BRAF (BRAF V600E) and MEK. The majority of patients with tumors that have higher expression of BRAF V600E show poorer prognosis than patients with a lower level of the mutated protein. Based on the molecular basis of melanoma, these findings are supported by distinct tumor phenotypes determined from differences in tumor heterogeneity and protein expression profiles. With these aspects in mind, continued challenges are to: (1) deconvolute the complexity and heterogeneity of MM; (2) identify the signaling pathways involved; and (3) determine protein expression to develop targeted therapies. Here, we provide an overview of the results from protein expression in MM and the link to disease presentation in a variety of tumor phenotypes and how these will overcome the challenges of clinical problems and suggest new promising approaches in metastatic melanoma and cancer therapy.